Pasithea Therapeutics Corp
Research Pasithea Therapeutics Corp (KTTA) on Bullrun: market cap USD 14.97M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerKTTA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 14.97M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 5.27M
- Free cash flow-USD 4.71M
Valuation Snapshot
latest market cap is USD 14.97M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 20.43M | -USD 15.21M | n/a | -2.91 | USD 55.16M | n/a | USD 55.22M |
| FY2024 | USD 0 | -USD 13.90M | -USD 13.92M | n/a | -12.69 | USD 6.92M | USD 0 | USD 14.78M |
| FY2023 | USD 0 | -USD 15.96M | -USD 12.85M | n/a | -0.42 | USD 16.33M | USD 81.68K | USD 23.40M |
| FY2022 | USD 486.56K | -USD 13.94M | -USD 14.67M | 76.7% | -1.76 | USD 33.09M | USD 504.38K | USD 42.50M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 14.97M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 29.79M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 4.39M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 7.71M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 18.78M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 40.72M | n/a | n/a | n/a |
About Pasithea Therapeutics Corp
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Pasithea Therapeutics Corp's market cap?
Pasithea Therapeutics Corp's market capitalization is USD 14.97M.
What does Pasithea Therapeutics Corp do?
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.